{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Skullerud KH"],"funding":["Celgene","Amgen","Oslo University Hospital"],"pubmed_abstract":["<h4>Background</h4>Genital erosive lichen planus (GELP) is a genital subtype of lichen planus, a chronic autoimmune inflammatory disease of unknown aetiology. In women, GELP is characterised by painful vulvo-vaginal mucosal erosions and scarring, often resulting in poor sexual health and reduced quality of life. Treatment options are limited and often with little effect. Apremilast, a phosphodiesterase 4-inhibitor, has been shown to have a positive effect on psoriasis and other inflammatory skin diseases. We aim to investigate the effect and safety of peroral apremilast in women with GELP in a randomised placebo-controlled double-blinded clinical trial.<h4>Methods</h4>We will recruit 42 adult women with characteristic clinical and/or histological features of moderate-to-severe GELP from a "],"journal":["Trials"],"pagination":["469"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8290211"],"repository":["biostudies-literature"],"pubmed_title":["Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial."],"pmcid":["PMC8290211"],"pubmed_authors":["Gjersvik P","Helgesen ALO","Skullerud KH","Pripp AH","Qvigstad E"],"additional_accession":[]},"is_claimable":false,"name":"Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.","description":"<h4>Background</h4>Genital erosive lichen planus (GELP) is a genital subtype of lichen planus, a chronic autoimmune inflammatory disease of unknown aetiology. In women, GELP is characterised by painful vulvo-vaginal mucosal erosions and scarring, often resulting in poor sexual health and reduced quality of life. Treatment options are limited and often with little effect. Apremilast, a phosphodiesterase 4-inhibitor, has been shown to have a positive effect on psoriasis and other inflammatory skin diseases. We aim to investigate the effect and safety of peroral apremilast in women with GELP in a randomised placebo-controlled double-blinded clinical trial.<h4>Methods</h4>We will recruit 42 adult women with characteristic clinical and/or histological features of moderate-to-severe GELP from a ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-05-07T19:54:26.981Z","creation":"2022-02-10T22:05:07.753Z"},"accession":"S-EPMC8290211","cross_references":{"pubmed":["34284808"],"doi":["10.1186/s13063-021-05428-w"]}}